James Nam

Vemurafenib adjuvant therapy does not improve disease-free survival among patients with resected stage IIC to IIIB melanoma.

Pembrolizumab leads to a durable complete response with low rates of relapse — even 2 years after discontinuation — and may cure a subset of patients with metastatic melanoma.

Researchers examined the changes in levels of different proteins in cancer cell lines after treatment with melatonin analogues

Dabrafenib plus trametinib is the first adjuvant therapy indicated specifically for melanoma with the BRAFV600 mutation.

Patients who received adjuvant therapy with dabrafenib and trametinib had an estimated 3-year rate of relapse-free survival.

More than 50% of patients with melanoma do not benefit from therapy with ipilimumab and BRAF-inhibitors.

The standard dose pembrolizumab along with 4 doses of reduced dose ipilimumab may have good outcomes for patients with advanced melanoma.

Pediatric patients with unresectable or metastatic melanomaare now included in the indication of IV ipilimumab.